Skip to main content
SpringerLink
Log in

Post-Hoc Analysis of a Head-to-Head Hyaluronic Acid Comparison in Knee Osteoarthritis Using the 2004 OMERACT-OARSI Responder Criteria

  • Original Research Article
  • Published:
Clinical Drug Investigation Aims and scope Submit manuscript

Abstract

Background and objective:

Several intra-articular hyaluronic acid products are available for treating osteoarthritis (OA) of the knee, including hylan G-F 20 and the bioengineered straight-chain hyaluronic acid (Bio-HA). A recently published study in patients with knee OA demonstrated non-inferiority with regard to efficacy, using the pain subscore of the Western Ontario and McMaster Universities Osteoarthritis Index (safety data favoured Bio-HA with regard to knee effusions). However, the Osteoarthritis Research Society International (OARSI) Standing Committee for Clinical Trials Response Criteria Initiative together with the Outcome Measures in Rheumatology (OMERACT) committee have published new response criteria for OA clinical trials. These criteria focus on change in pain and physical function. The aim of this study was to reanalyse the data from the original comparative study of hylan G-F 20 and Bio-HA in knee OA utilising the new OMERACT-OARSI response criteria.

Methods:

The original study was a prospective, multicentre, randomized, double-blind trial of 321 patients with knee OA who received hylan G-F 20 or Bio-HA via three intra-articular injections 1 week apart. This post-hoc analysis of the data using the modified OMERACT-OARSI responder criteria focused only on efficacy.

Results:

Using the OMERACT-OARSI criteria, 112 of the 157 patients (71%) receiving Bio-HA were considered to have a response compared with 99 of the 158 patients (63%) receiving hylan G-F 20 (p = 0.10).

Conclusions:

Application of the new, standardized definition of a responder in OA clinical trials to the existing data reinforces that Bio-HA is non-inferior to hylan G-F 20 for knee OA. Both agents were similarly well tolerated, but Bio-HA was associated with a lower incidence of effusions, suggesting that Bio-HA has an improved risk-benefit profile compared with hylan G-F 20.

This is a preview of subscription content, log in via an institution to check access.

Access this article

Log in via an institution

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Institutional subscriptions

Fig. 1
Table I
Table II
Fig. 2
Table III
Fig. 3

Similar content being viewed by others

Notes

  1. The use of trade names is for product identification purposes only and does not imply endorsement.

References

  1. McConnell S, Kolopack P, Davis AM. The Western Ontario and McMaster Universities Osteoarthritis Index (WOMAC): a review of its utility and measurement properties. Arthritis Rheumatism 2001 Oct; 45(5): 453–61

    Article  PubMed  CAS  Google Scholar 

  2. Altman R, Brandt K, Hochberg M, et al. Design and conduct of clinical trials in patients with osteoarthritis: recommendations from a task force of the Osteoarthritis Research Society. Results from a workshop. Osteoarthr Cartil 1996 Dec; 4(4): 217–43

    Article  CAS  Google Scholar 

  3. Bellamy N, Kirwan J, Boers M, et al. Recommendations for a core set of outcome measures for future phase III clinical trials in knee, hip, and hand osteoarthritis: consensus development at OMERACT III. J Rheumatol 1997 Apr; 24(4): 799–802

    PubMed  CAS  Google Scholar 

  4. Lequesne M, Brandt K, Bellamy N, et al. Guidelines for testing slow acting drugs in osteoarthritis. J Rheumatol 1994 Sep; 41: 65–71; discussion 2-3

    CAS  Google Scholar 

  5. Pham T, Van Der Heijde D, Lassere M, et al. Outcome variables for osteoarthritis clinical trials: the OMERACT-OARSI set of responder criteria. J Rheumatol 2003 Jul; 30(7): 1648–54

    PubMed  Google Scholar 

  6. Pham T, van der Heijde D, Altman RD, et al. OMERACT-OARSI initiative: Osteoarthritis Research Society International set of responder criteria for osteoarthritis clinical trials revisited. Osteoarthr Cartil 2004 May; 12(5): 389–99

    Article  PubMed  CAS  Google Scholar 

  7. Balazs EA. The physical properties of synovial fluid and the special role of hyaluronic acid. In: Helfet AJ, editor. Disorders of the knee. Philadelphia (PA): Lippincott, 1974: 63–74

    Google Scholar 

  8. Altman RD, Moskowitz R. Intraarticular sodium hyaluronate (Hyalgan) in the treatment of patients with osteoarthritis of the knee: a randomized clinical trial. Hyalgan Study Group. J Rheumatol 1998 Nov; 25(11): 2203–12

    PubMed  CAS  Google Scholar 

  9. Dixon AS, Jacoby RK, Berry H, et al. Clinical trial of intra-articular injection of sodium hyaluronate in patients with osteo-arthritis of the knee. Curr Med Res Opin 1988; 11(4): 205–13

    Article  PubMed  CAS  Google Scholar 

  10. Jones AC, Pattrick M, Doherty S, et al. Intra-articular hyaluronic acid compared to intra-articular triamcinolone hexacetonide in inflammatory knee osteoarthritis. Osteoarthr Cartil 1995 Dec; 3(4): 269–73

    Article  PubMed  CAS  Google Scholar 

  11. Karlsson J, Sjogren LS, Lohmander LS. Comparison of two hyaluronan drugs and placebo in patients with knee osteoarthritis: a controlled, randomized, double-blind, parallel-design multicentre study. Rheumatology (Oxford, England) 2002 Nov; 41(11): 1240–8

    Article  CAS  Google Scholar 

  12. Leopold SS, Redd BB, Warme WJ, et al. Corticosteroid compared with hyaluronic acid injections for the treatment of osteoarthritis of the knee: a prospective, randomized trial. J Bone Joint Surg 2003 Jul; 85-A(7): 1197–203

    PubMed  Google Scholar 

  13. Lohmander LS, Dalen N, Englund G, et al. Intra-articular hyaluronan injections in the treatment of osteoarthritis of the knee: a randomised, double blind, placebo controlled multicentre trial. Hyaluronan Multicentre Trial Group. Ann Rheum Dis 1996 Jul; 55(7): 424–31

    Article  PubMed  CAS  Google Scholar 

  14. Puhl W, Bernau A, Greiling H, et al. Intra-articular sodium hyaluronate in osteoarthritis of the knee: a multicenter, double-blind study. Osteoarthr Cartil 1993 Oct; 1(4): 233–41

    Article  PubMed  CAS  Google Scholar 

  15. Wobig M, Dickhut A, Maier R, et al. Viscosupplementation with hylan G-F 20: a 26-week controlled trial of efficacy and safety in the osteoarthritic knee. Clin Ther 1998 May–Jun; 20(3): 410–23

    Article  PubMed  CAS  Google Scholar 

  16. Wu JJ, Shih LY, Hsu HC, et al. The double-blind test of sodium hyaluronate (ARTZ) on osteoarthritis of the knee. Zhonghua Yi Xue Za Zhi 1997 Feb; 59(2): 99–106

    PubMed  CAS  Google Scholar 

  17. Balazs EA, Denlinger JL. Viscosupplementation: a new concept in the treatment of osteoarthritis. J Rheumatol 1993 Aug; 39: 3–9

    CAS  Google Scholar 

  18. Gomis A, Pawlak M, Balazs EA, et al. Effects of different molecular weight elastoviscous hyaluronan solutions on articular nociceptive afferents. Arthr Rheum 2004 Jan; 50(1): 314–26

    Article  CAS  Google Scholar 

  19. Weiss C, Band PA. Basic principles underlying the development of viscosupplementation for the treatment of osteoarthritis. J Clin Rheumatol 1999; 3: S2–S11

    Google Scholar 

  20. Kirchner M, Marshall D. A double-blind randomized controlled trial comparing alternate forms of high molecular weight hyaluronan for the treatment of osteoarthritis of the knee. Osteoarthr Cartil 2006 Feb; 14(2): 154–62

    Article  PubMed  CAS  Google Scholar 

  21. Altman R, Asch E, Bloch D, et al. Development of criteria for the classification and reporting of osteoarthritis: classification of osteoarthritis of the knee. Diagnostic and Therapeutic Criteria Committee of the American Rheumatism Association. Arthr Rheum 1986 Aug; 29(8): 1039–49

    Article  CAS  Google Scholar 

  22. Bolnot-Delmas D, Buch JP, Zeidler H, et al. Ro 15-8081 in osteoarthritis of hip and knee: a double-blind placebo-controlled multicentre dose-ranging study on analgesia. Pain 1996 Jan; 64(1): 99–105

    Article  PubMed  CAS  Google Scholar 

  23. Bellamy N, Bell MJ, Goldsmith CH, et al. The effectiveness of hylan G-F 20 in patients with knee osteoarthritis: an application of two sets of response criteria developed by the OARSI and one set developed by OMERACT-OARSI. Osteoarthr Cartil 2005 Feb; 13(2): 104–10

    Article  PubMed  Google Scholar 

  24. Mazières B, Hucher M, Zaïm M, et al. Effect of chondroitin sulphate on symptomatic knee osteoarthritis: a multicentre, randomized, placebo-controlled study. Ann Rheum Dis 2007; 66: 639–45

    Article  PubMed  Google Scholar 

  25. Gentelle-Bonnassies S, LeClaire P, Mezieres M, et al. Comparison of the responsiveness of symptomatic outcome measures in knee osteoarthritis. Arthritis Care Res 2000; 13(5): 280–5

    Article  PubMed  CAS  Google Scholar 

  26. Anderson JJ, Bolognese JA, Felson DT. Comparison of rheumatoid arthritis clinical trial outcome measures: a simulation study. Arthr Rheum 2003 Nov; 48(11): 3031–8

    Article  Google Scholar 

  27. Goldberg VM, Coutts RD. Pseudoseptic reactions to hylan viscosupplementation: diagnosis and treatment. Clin Orth Rel Res 2004 Feb; 419: 130–7

    Article  Google Scholar 

  28. Leopold SS, Warme WJ, Pettis PD, et al. Increased frequency of acute local reaction to intra-articular hylan GF-20 (Synvisc) in patients receiving more than one course of treatment. J Bone Joint Surg 2002 Sep; 84-A(9): 1619–23

    PubMed  Google Scholar 

  29. Pullman-Mooar S, Mooar P, Sieck M, et al. Are there distinctive inflammatory flares after hylan G-F 20 intraarticular injections? J Rheumatol 2002 Dec; 29(12): 2611–4

    PubMed  CAS  Google Scholar 

  30. Onel E, Kerney DL, Kolsun K, et al. Patients’ perceptions of the effect of Euflexxa™ (1% sodium hyaluronate) on knee pain induced difficulties with activities of daily living and social or leisure activities. Poster presented at the 2007 World Congress on Osteoarthritis; 2007 Dec 6–9; Fort Lauderdale (FL)

Download references

Acknowledgements

Ferring Pharmaceuticals, Inc. provided funding for this study and for preparation of the manuscript. The authors would like to thank Catherine Rees of Wolters Kluwer Health for technical editing assistance on this manuscript. Drs Erol Onel and Kathleen Kolsun are employed by Ferring Pharmaceuticals, Inc. Dr Kauffman serves as an occasional speaker for Ferring Pharmaceuticals, Inc.

Author information

Authors and Affiliations

  1. Ferring Pharmaceuticals, Inc., 4 Gatehall Drive, Third Floor, Parsipanny, New Jersey, 07054, USA

    Erol Onel & Kathleen Kolsun

  2. Sacramento Knee and Sports Medicine, Sacramento, California, USA

    Jeffrey I. Kauffman

Authors
  1. Erol Onel
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. Kathleen Kolsun
    View author publications

    You can also search for this author in PubMed Google Scholar

  3. Jeffrey I. Kauffman
    View author publications

    You can also search for this author in PubMed Google Scholar

Corresponding author

Correspondence to Erol Onel.

Additional information

Outcome Measures in Rheumatology (OMERACT) committee and Osteoarthritis Research Society International (OARSI) Standing Committee for Clinical Trials Response Criteria Initiative

Rights and permissions

Reprints and permissions

About this article

Cite this article

Onel, E., Kolsun, K. & Kauffman, J.I. Post-Hoc Analysis of a Head-to-Head Hyaluronic Acid Comparison in Knee Osteoarthritis Using the 2004 OMERACT-OARSI Responder Criteria. Clin. Drug Investig. 28, 37–45 (2008). https://doi.org/10.2165/00044011-200828010-00005

Download citation

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.2165/00044011-200828010-00005

Keywords

Search

Navigation